WO2005121376A3 - Hiv variants showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant variant - Google Patents

Hiv variants showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant variant Download PDF

Info

Publication number
WO2005121376A3
WO2005121376A3 PCT/EP2005/006262 EP2005006262W WO2005121376A3 WO 2005121376 A3 WO2005121376 A3 WO 2005121376A3 EP 2005006262 W EP2005006262 W EP 2005006262W WO 2005121376 A3 WO2005121376 A3 WO 2005121376A3
Authority
WO
WIPO (PCT)
Prior art keywords
variant
diagnostic assays
protease inhibitors
resistance mechanism
detecting
Prior art date
Application number
PCT/EP2005/006262
Other languages
French (fr)
Other versions
WO2005121376A2 (en
Inventor
Pauline Johanna Schipper
Maarseveen Noortje Mariann Van
Monique Johanna Gezina Nijhuis
Charles Achim Bernard Boucher
Original Assignee
Umc Utrecht Holding Bv
Pauline Johanna Schipper
Maarseveen Noortje Mariann Van
Monique Johanna Gezina Nijhuis
Charles Achim Bernard Boucher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04076669A external-priority patent/EP1605064A1/en
Application filed by Umc Utrecht Holding Bv, Pauline Johanna Schipper, Maarseveen Noortje Mariann Van, Monique Johanna Gezina Nijhuis, Charles Achim Bernard Boucher filed Critical Umc Utrecht Holding Bv
Publication of WO2005121376A2 publication Critical patent/WO2005121376A2/en
Publication of WO2005121376A3 publication Critical patent/WO2005121376A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to novel Human Immunodeficiency Virus 1 (HIV-1) variants that are resistant against protease inhibitors including the high genetic barrier protease inhibitor R0033-4649 and show mutations not in the protease itself but in the viral Gag protein (Matrix and Capsid) and the viral cleavage sites thus establishing a novel resistance mechanism. The invention further relates to diagnostic assays for determining the presence in a sample of the HIV variant.
PCT/EP2005/006262 2004-06-07 2005-06-07 Hiv variants showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant variant WO2005121376A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04076669A EP1605064A1 (en) 2004-06-07 2004-06-07 HIV Variant showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant virus
EP04076669.3 2004-06-07
EP04078431.6 2004-12-20
EP04078431 2004-12-20

Publications (2)

Publication Number Publication Date
WO2005121376A2 WO2005121376A2 (en) 2005-12-22
WO2005121376A3 true WO2005121376A3 (en) 2006-08-10

Family

ID=35079127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006262 WO2005121376A2 (en) 2004-06-07 2005-06-07 Hiv variants showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant variant

Country Status (1)

Country Link
WO (1) WO2005121376A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738365B2 (en) 2013-05-31 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs
EP3290412A1 (en) 2016-08-31 2018-03-07 Università degli Studi di Siena Hiv-1 nucleocapsid inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073511A1 (en) * 1999-05-28 2000-12-07 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073511A1 (en) * 1999-05-28 2000-12-07 Virco Nv New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALLY FRANK ET AL: "Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 16, no. 13, 1 September 2000 (2000-09-01), pages 1209 - 1213, XP002352919, ISSN: 0889-2229 *
DESAI S M ET AL: "MOLECULAR CLONING AND PRIMARY NUCLEOTIDE SEQUENCE ANALYSIS OF A DISTINCT HUMAN IMMUNODEFICIENCY VIRUS ISOLATE REVEAL SIGNIFICANT DIVERGENCE IN ITS GENOMIC SEQUENCES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 83, no. 21, 1986, pages 8380 - 8384, XP002352918, ISSN: 0027-8424 *
GATANAGA HIROYUKI ET AL: "Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 8, 22 February 2002 (2002-02-22), pages 5952 - 5961, XP001121729, ISSN: 0021-9258 *
RATNER L ET AL: "COMPLETE NUCLEOTIDE SEQUENCE OF THE AIDS VIRUS, HTLV-III", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 313, 24 January 1985 (1985-01-24), pages 277 - 284, XP000572709, ISSN: 0028-0836 *
ZHANG Y-M ET AL: "Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 9, 1997, pages 6662 - 6670, XP002316390, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2005121376A2 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
Contreras-Galindo et al. Detection of HERV-K (HML-2) viral RNA in plasma of HIV type 1-infected individuals
Pettit et al. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease
Ott et al. Retroviruses have differing requirements for proteasome function in the budding process
Westby et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
Tisdale Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors
Madden et al. Host cell-intrinsic innate immune recognition of SARS-CoV-2
Shi et al. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors
Zhang et al. Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals
DE60233942D1 (en) USE OF FKBP CHAPERONS AS EXPRESSION TOOLS
ATE449962T1 (en) MICROCHIP-BASED SYSTEM FOR HIV DIAGNOSTICS
Contreras-Galindo et al. A new Real-Time-RT-PCR for quantitation of human endogenous retroviruses type K (HERV-K) RNA load in plasma samples: increased HERV-K RNA titers in HIV-1 patients with HAART non-suppressive regimens
WO2001059457A3 (en) Assay for detection of viral fusion inhibitors
Warren et al. The HIV-1 latent reservoir is largely sensitive to circulating T cells
FR3044312B1 (en) MUTUATED HEV POLYPEPTIDES AND THEIR USE FOR THE ASSAY OF ANTI-HEV ANTIBODIES
WO2005121376A3 (en) Hiv variants showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant variant
Nijhuis et al. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V
Saphire et al. trans-Complementation rescue of cyclophilin A-deficient viruses reveals that the requirement for cyclophilin A in human immunodeficiency virus type 1 replication is independent of its isomerase activity
WO2003060098A3 (en) Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to hiv-1 rna
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
US20080233558A1 (en) Inhibitors of viral entry screening method
Stevens et al. Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir
WO2004005889A3 (en) Detection of drug-resistant human immunodeficiency virus
BRPI0514156A (en) in vitro hiv DNA detection and quantification method by quantitative pcr
Bansal et al. T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles
WO2001079542A3 (en) Hiv detection assay and reagents therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase